Annals of Surgical Oncology

Race and Gender Disparities in Access to Parathyroidectomy: A Need to Change Processes for Diagnosis and Referral to Surgeons.  28:476-483. 2021

The Impact of Residential Segregation on Pancreatic Cancer Diagnosis, Treatment, and Mortality 2020

Effect of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Malignancy Rates in Thyroid Nodules: How to Counsel Patients on Extent of Surgery.  26:93-97. 2019

Select Choices in Benign Breast Disease: An Initiative of the American Society of Breast Surgeons for the American Board of Internal Medicine Choosing Wisely^® Campaign.  25:2795-2800. 2018

STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro.  25:792-800. 2018

Benchmarking the American Society of Breast Surgeon Member Performance for More Than a Million Quality Measure-Patient Encounters.  25:501-511. 2018

Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.  24:3674-3682. 2017

Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials.  24:2855-2862. 2017

Optimizing Outpatient Pain Management After Thyroid and Parathyroid Surgery: A Two-Institution Experience.  24:1951-1957. 2017

Breast Malignancies in Children: Presentation, Management, and Survival.  24:1482-1491. 2017

Intraoperative Parathyroid Hormone Levels at 5 min Can Identify Multigland Disease.  24:733-738. 2017

Measures of Appropriateness and Value for Breast Surgeons and Their Patients: The American Society of Breast Surgeons Choosing Wisely ^®Initiative.  23:3112-3118. 2016

Antiplatelet and Anticoagulant Medications Significantly Increase the Risk of Postoperative Hematoma: Review of over 4500 Thyroid and Parathyroid Procedures.  23:2874-2882. 2016

Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy.  23:2715-2722. 2016

Compromised Outcome of Papillary Thyroid Cancer at Low-Volume Treatment Centers: Practice Makes Perfect?.  23:355-357. 2016

[^99mTc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial.  22:3708-3715. 2015

Clinical and Socioeconomic Factors Influence Treatment Decisions in Graves’ Disease.  22:1196-1199. 2015

Outcomes After Subtotal Parathyroidectomy for Primary Hyperparathyroidism due to Hyperplasia: Significance of Whole vs. Partial Gland Remnant.  22:966-971. 2015

All Thyroid Ultrasound Evaluations are Not Equal: Sonographers Specialized in Thyroid Cancer Correctly Label Clinical N0 Disease in Well Differentiated Thyroid Cancer.  22:422-428. 2015

CaPTHUS Scoring Model in Primary Hyperparathyroidism: Can It Eliminate the Need for ioPTH Testing?.  22:1191-1195. 2015

Chasing Calcitonin: Reoperations for Medullary Thyroid Carcinoma.  22:7-8. 2015

Justified Follow-Up: A Final Intraoperative Parathyroid Hormone (ioPTH) Over 40 pg/mL is Associated with an Increased Risk of Persistence and Recurrence in Primary Hyperparathyroidism.  22:454-459. 2015

Lymph Node Metastases do not Impact Survival in Follicular Variant Papillary Thyroid Cancer.  22:158-163. 2015

Preventing Postoperative Hypocalcemia in Patients with Graves Disease: A Prospective Study.  22:952-958. 2015

Surgical Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy and Breast Magnetic Resonance Imaging: Results of a Secondary Analysis of TBCRC 017.  22:75-81. 2015

The Use of Modified Four-Dimensional Computed Tomography in Patients with Primary Hyperparathyroidism: An Argument for the Abandonment of Routine Sestamibi Single-Positron Emission Computed Tomography (SPECT).  22:139-145. 2015

Erratum to: Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival (Annals of Surgical Oncology, DOI: 10.1245/S10434-014-3486-Z).  21:1538. 2014

Evaluation of two inflammation-based prognostic scores in patients with resectable gallbladder carcinoma.  21:449-457. 2014

Assessment of Erlotinib as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer Patients.  21:4263-4269. 2014

Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.  21:1530-1537. 2014

Failure of Radioactive Iodine in the Treatment of Hyperthyroidism.  21:4174-4180. 2014

Hesperetin Activates the Notch1 Signaling Cascade, Causes Apoptosis, and Induces Cellular Differentiation in Anaplastic Thyroid Cancer.  21:497-504. 2014

Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657).  21:2889-2896. 2014

Posterior 'superior mesenteric artery first' approach for resection of locally advanced pancreatic cancer.  21:1927-1928. 2014

Radioactive iodine remnant uptake after completion thyroidectomy: Not such a complete cancer operation.  21:1379-1383. 2014

Silencing of UCHL1 by CpG Promoter Hyper-methylation is Associated with Metastatic Gastroenteropancreatic Well-Differentiated Neuroendocrine (Carcinoid) Tumors.  21:672-679. 2014

Surgeon and Staff Radiation Exposure During Radioguided Parathyroidectomy at a High-Volume Institution.  21:3853-3858. 2014

Thyroidectomy as primary treatment optimizes body mass index in patients with hyperthyroidism.  21:2303-2309. 2014

MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through akt inhibition.  20:3862-3868. 2013

Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.  20:3059-3065. 2013

Minimal benefit to subsequent intraoperative parathyroid hormone testing after all four glands have been identified.  20:4200-4204. 2013

Multigland disease and slower decline in intraoperative PTH characterize mild primary hyperparathyroidism.  20:4205-4211. 2013

Presentation, management, and outcomes of hyperparathyroidism in octogenarians and nonagenarians.  20:4195-4199. 2013

Comparative evaluation of [^99mTc]tilmanocept for sentinel lymph node mapping in breast cancer patients: Results of two phase 3 trials.  20:2590-2599. 2013

Parathyroid cryopreservation after parathyroidectomy: A worthwhile practice?.  20:2256-2260. 2013

Disparities in pancreas cancer care.  20:2078-2087. 2013

Impact of lymph node ratio on survival in papillary thyroid cancer.  20:1906-1911. 2013

Doing away with the rule of 10 %.  20:1403-1404. 2013

Hereditary medullary thyroid cancer: Age-appropriate thyroidectomy improves disease-free survival.  20:1451-1455. 2013

Diversity of stage III melanoma in the era of sentinel lymph node biopsy.  20:956-963. 2013

Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.  20:640-645. 2013

Sestamibi imaging for primary hyperparathyroidism: The impact of surgeon interpretation and radiologist volume.  19:3827-3831. 2012

Surveillance of small rectal carcinoid tumors in the absence of metastatic disease.  19:3486-3490. 2012

The role of gender in primary hyperparathyroidism: Same disease, different presentation.  19:2958-2962. 2012

Sestamibi-negative patients: To operate or image?.  19:2086-2087. 2012

Does the final intraoperative PTH level really have to fall into the normal range to signify cure?.  19:1862-1867. 2012

Adverse effects of smoking on postoperative outcomes in cancer patients.  19:1430-1438. 2012

Is focused minimally invasive parathyroidectomy appropriate for patients with familial primary hyperparathyroidism?.  19:1264-1268. 2012

Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.  19:973-980. 2012

Presurgical localization of parathyroid adenomas with magnetic resonance imaging at 3.0 T: An adjunct method to supplement traditional imaging.  19:981-989. 2012

Limitations of the ACS NSQIP in thyroid surgery.  18:3529-3530. 2011

Does previous head and neck irradiation increase the chance of multigland disease in patients with hyperparathyroidism?.  18:2240-2244. 2011

Inadequate cytology of thyroid nodules. Repeat it or live with it.  18:1222-1223. 2011

Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer.  18:1506-1511. 2011

A comparison of the ligasure and harmonic scalpel in thyroid surgery: A single institution review.  18:214-218. 2011

Guideline recommended gastric cancer care in the elderly: Insights into the applicability of cancer trials to real world.  18:26-33. 2011

What is the added benefit of cervical ultrasound to ^99mTc- sestamibi scanning in primary hyperparathyroidism?.  18:2907-2911. 2011

25-Hydroxyvitamin D status does not affect intraoperative parathyroid hormone dynamics in patients with primary hyperparathyroidism.  17:2958-2962. 2010

Minimal disease in the sentinel lymph node: How to best measure sentinel node micrometastases to predict risk of additional non-sentinel lymph node disease.  17:2909-2919. 2010

Extremity soft tissue sarcoma care in the elderly: Insights into the generalizability of NCI cancer trials.  17:1732-1738. 2010

Body mass index does not affect postoperative morbidity and oncologic outcomes of total mesorectal excision for rectal adenocarcinoma.  17:1606-1613. 2010

Factors associated with false-negative sentinel lymph node biopsy in melanoma patients.  17:709-717. 2010

Utility of intraoperative PTH for primary hyperparathyroidism due to multigland disease.  16:3450-3454. 2009

Papillary thyroid microcarcinomas: Big decisions for a small tumor.  16:3132-3139. 2009

Inhibition of phosphatidylinositol 3-kinase/akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors.  16:2936-2942. 2009

Disparities in gastric cancer outcomes among Asian ethnicities in the USA.  16:2433-2441. 2009

Combination therapy with histone deacetylase inhibitors and lithium chloride: A novel treatment for carcinoid tumors.  16:481-486. 2009

Older age and larger tumor size predict malignancy in Hürthle cell neoplasms of the thyroid.  15:2842-2846. 2008

Suberoyl bishydroxamic acid activates Notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.  15:2600-2605. 2008

The influence of surgical approach on quality of life after parathyroid surgery.  15:1559-1565. 2008

The utility of metaiodobenzylguanidine (MIBG) scintigraphy in patients with pheochromocytoma.  15:900-905. 2008

Author reply [2].  15:380-381. 2008

Isolated adrenal mass in patients with a history of cancer: Remember pheochromocytoma.  14:2358-2362. 2007

The negative sestamibi scan: Is a minimally invasive parathyroidectomy still possible?.  14:2363-2366. 2007

Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response.  14:2150-2158. 2007

Local/cervical block anesthesia versus general anesthesia for minimally invasive parathyroidectomy: What are the advantages?.  14:744-749. 2007

Radioguided parathyroidectomy in patients with familial hyperparathyroidism.  14:739-743. 2007

Characteristics and treatment of metaplastic breast cancer: Analysis of 892 cases from the national cancer data base.  14:166-173. 2007

Is tumor size the best predictor of outcome for papillary thyroid cancer?.  13:1524-1528. 2006

Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.  13:1145-1155. 2006

Fine-needle aspiration optimizes surgical management in patients with thyroid cancer.  13:859-863. 2006

Trends in hospital and surgeon volume and operative mortality for cancer surgery.  13:851-858. 2006

Long-term outcomes in patients with calciphylaxis from hyperparathyroidism.  13:96-102. 2006

Are minimally invasive techniques for ablation of breast cancer ready for "prime time"?.  11:115-116. 2004

The utility of frozen section evaluation for follicular thyroid lesions.  11:94-98. 2004

Expression of p53 and proliferation index as prognostic factors in gastrointestinal sarcomas.  10:190-195. 2003

Recent insights into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma.  10:839-851. 2003

Annals of surgical oncology impact factor/rating has dramatically increased..  10:1-3. 2003

The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined..  10:65-71. 2003

Long-term complications of breast-conservation therapy: Can the incidence be reduced?.  9:524-525. 2002

Editorial commentary on scientific fraud.  9:419-420. 2002

Palliative thyroidectomy for malignant lymphoma of the thyroid.  9:907-911. 2002

Primary thyroid lymphoma: Can the diagnosis be made solely by fine-needle aspiration?.  9:298-302. 2002

Utilization of sentinel lymph node mapping to determine pathologic outcomes for patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.  9:217-219. 2002

Sentinel node biopsy for cutaneous melanoma in the head and neck.  8:716-719. 2001

Sentinel node biopsy for cutaneous melanoma in the head and neck..  8:716-719. 2001

Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas..  8:101-108. 2001

Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas.  8:101-108. 2001

Multimodality treatment of merkel cell carcinoma: Case series and literature review of 1024 cases.  8:204-208. 2001

Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm).  7:87-97. 2000

Current status of endocrine therapy for advanced breast cancer.  6. 1999

Future directions in endocrine treatment of advanced breast cancer.  6. 1999

Role of new endocrine therapies in the treatment of advanced breast cancer: Introduction.  6. 1999

Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer.  6. 1999

Refining the optimal technical approach for sentinel node localization in breast cancer patients.  6:418-419. 1999

Microstaging of sentinel lymph nodes.  6:15-16. 1999

The 1999 James Ewing lecture: In pursuit of molecules of oncogenesis and neoplastic therapy.  6:528-541. 1999

Molecular oncogene markers and their significance in cutaneous malignant melanoma.  5:253-260. 1998

Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells.  5:279-286. 1998

Indications for axillary dissection in T1 breast cancer.  5:4-8. 1998

Role of axillary lymph node dissection after tumor downstaging.  5:665-666. 1998

Optimal surgical treatment of invasive lobular carcinoma of the breast.  4:545-550. 1997

The society at a crossroads: Milestones and imperatives for cancer clinical trials.  4:523-539. 1997

Topographic genotyping of colorectal carcinoma: From a molecular carcinogenesis model to clinical relevance.  4:269-278. 1997

Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial..  3:110-117. 1996

Local recurrence in malignant melanoma: Long-term results of the multiinstitutional randomized surgical trial.  3:446-452. 1996

Malignant potential in intestinal juvenile polyposis syndromes.  2:386-391. 1995

Insurance coverage of patients with breast cancer in the 1991 Commission on Cancer patient care evaluation study.  1:462-467. 1994

What is a surgical oncologist?.  1:2-4. 1994